 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
New AIDS Clinical Trials Unit Study OpensDecember 30, 2003 ACTG Study 5142A study to compare the effectiveness of three regimens for the initial treatment of HIV Infection The study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection. Eligibility:
The study will last for about three years. Exams and lab tests provided at no cost. Only TDF, EFV, LPV/r, and d4tXR will be provided by the study. Subjects receive $20 per study visit. Contact Alyssa or Lori at the ACTU at (206) 731-3184.  This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
|
 |
Email
Print-Friendly
Glossary
PDF
The Body: About The Body | Contact The Body | Site Policies | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
